
CURRICULUM VITAE

Full Name: Antoniou Aikaterini

Professional Address: Department of Pharmacology, Faculty of Medicine, School of Health Sciences
University of Ioannina, 45110 Ioannina, Greece.

Tel: +30 26510 07570 **Fax:** +30 26510 07859 **Mobile:** +30 6937288442

e-mail: kantoniou@uoi.gr

Position

Associate Professor of Pharmacology, Department of Pharmacology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Greece.

Research and/or Professional Experience

2019-present: Associate Professor of Pharmacology

2015-2018: President of National Organization for Medicines

2014 (July): Associate Professor, Department of Pharmacology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Greece.

2011 (November): Assistant Professor (tenured), Department of Pharmacology, Faculty of Medicine, School of Health Sciences, University of Ioannina, Greece.

2009–2010: Visiting Scientist, Department of Psychiatry and Neurobiology, INSERM, Paris, France (total: five months).

2008: Assistant Professor (tenure-track), Department of Pharmacology, Medical School, University of Ioannina, Greece.

2003: Lecturer, Department of Pharmacology, Medical School, University of Ioannina, Greece.

2002: Lecturer, Department of Pharmacology, Medical School, University of Athens, Greece.

July 2001–November 2002: Guest Scientist, National Institute on Drug Abuse, National Institutes of Health, Baltimore, USA (total: ten months).

1998-August 1999: Research Associate-Clinical Pharmacology, Laboratory of Biopharmaceutics and Pharmacokinetics, Pharmacy Department, University of Athens, Greece.

1997-2002: Research Associate, Department of Pharmacology, Medical School, University of Athens, Greece.

1995-1996: Post-doc Fellow, Department of Neuroscience, Division of Histology, Karolinska Institute, Stockholm, Sweden (total: 17 months).

1993-1995: Post-doc Fellow, Department of Pharmacology, Medical School, University of Athens, Greece.

1988-1992: PhD candidate, Department of Pharmacology, Medical School, University of Ioannina, Ioannina, Greece/ Department of Pharmacology, Medical School, University of Athens, Greece.

Research interests

- Mechanisms underlying the behavioral and neurobiological effects of psychotropics such as d-amphetamine, cocaine, caffeine, ketamine, alcohol and cannabinoids.
- Modeling of CNS disorders and their neurobiological substrates such as depression, psychosis, and drugs of abuse.
- Pharmacological evaluation (screening) of drugs/substances with CNS activity.
- Definition of specific phenotypes (including individual differences) which characterized by certain behavioral outcomes and accompanied by respective neurobiological indices.
- Investigation of neurobiological indices in first psychotic episode and depression adjusted for temperamental personality traits.

Funded research Grants

Total grants **as Principal Investigator** : 6

Total grants **as Collaborator** : 11

Total grants **as PhD candidate / Post-doc researcher** : 6

Selected Publications

1. Antoniou K, Kafetzopoulos E, Papadopoulou-Daifoti Z, Hyphantis T, Marselos M. D-amphetamine, cocaine and caffeine: a comparative study of acute effects on locomotor activity and behavioral patterns in rats. *NeurosciBiobehav Rev.* 1998; 23(2):189-96.**Antoniou K**, Papathanasiou G, Nomikos G, Hyphantis T, Papadopoulou-Daifoti Z. Antipsychotic drugs: A comparative study of acute effects on spontaneous locomotor activity and behavioural patterns in rats. *Europ Neuropsychopharm.* 2002; 12:324.Solinas M, Panlilio LV, **Antoniou K**, Pappas LA, Goldberg SR. The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl) -4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats. *J PharmacolExpTher.* 2003; 306(1):93-102.**Antoniou K**, Papathanasiou G, Panagis G, Nomikos GG, Hyphantis T, Papadopoulou-Daifoti Z. Individual responses to novelty predict qualitative differences in d-amphetamine-induced open field but not reward-related behaviors in rats. *Neuroscience.* 2004; 123(3):613-23.**Antoniou K**, Galanopoulos A, Vlachou S, Kourouli T, Nahmias V, Thermos K, Panagis G, Daifoti Z, Marselos M, Papahatjis D, Spyraiki C. Behavioral pharmacological properties of a novel cannabinoid 1',1'-dithiolane delta8-THC analog, AMG-3. *BehavPharmacol.* 2005; 16(5-6):499-510.Panagis G, **Antoniou K**, Thermos K, Papazoglou M, Mastrodimou N, Polissidis A, Vlachou S, Nahmias V, Kondylis M, Papahatjis D, Daifoti-Papadopoulou Z, Spyraiki C. Pharmacological profile of DPG-4 a new ligand for CB1 and CB2 cannabinoid receptors. *Review of Clinical Pharmacology and Pharmacokinetics-International Edition.* 2006; 20(2)263.Dalla C, **Antoniou K**, Kokras N, Drossopoulou G, Papathanasiou G, Bekris S, Daskas S, Papadopoulou-Daifoti Z. Sex differences in the effects of two stress paradigms on dopaminergic neurotransmission. *Physiology & behavior* 2008; 93(3): 595-605.Polissidis A, Chouliara O, Galanopoulos A, Marselos M, Papadopoulou-Daifoti Z and **Antoniou K**. Behavioral and dopaminergic alterations induced by a low dose of WIN 55,212-2 in a conditioned place preference procedure. *Life Sciences.* 2009; 85(5-6):248-254.**Antoniou K**, Bekris S, Saranti M, Stathis P, Rimikis M, Papadopoulou-Daifoti Z. The effects of antipsychotic drugs on serotonergic activity in the rat hippocampus. *Europ Neuropsychopharm* 2010; 10(5)315-324.

10. Rentesi G, **Antoniou K**, Marselos M, Fotopoulos A, Alboycharali J, Konstandi M. Long-term consequences of early maternal deprivation in serotonergic activity and HPA function in adult rat. *Neuroscience letters* 2010; 480(1):7-11.

11. Polissidis A, Chouliara O, Galanopoulos A, Rentesi G, Dosi M, Hyphantis T, Marselos M, Papadopoulou-Daifoti Z, Spyraiki C, Tzavara ET and **Antoniou K**. Individual differences in the effects of cannabinoidson motor activity, dopaminergic activity and DARPP-32 phosphorylation in distinct regions of the brain. *Int J Neuropsychopharmacology* 2010; 13(9):1175-91.Galanopoulos A, Polissidis A, Papadopoulou-Daifoti Z, Nomikos GG, **Antoniou K**. Δ(9)-THC and WIN55,212-2 affect brain tissue levels of excitatory amino acids in a phenotype-, compound-, dose-, and region-specific manner. *Behav Brain Res.* 2011; 224(1):65-72.Kokras N., Dalla C., Sideris AC., Dendi A., Mikail HG., **Antoniou K**, Papadopoulou-Daifoti Z. Behavioral sexual dimorphism in models of anxiety and depression due to changes in HPA axis activity. *Neuropharmacology.* 2012; 62(1):436-45. doi: 10.1016/j.neuropharm.2011.08.025.Kokras N, Dalla C, Sideris A, Dendi A, Mikail HG, **Antoniou K** and Papadopoulou-Daifoti Z. The sex-differentiated stress response in models of anxiety and depression: corticosterone and estrous cycle effects. *Neuropharmacology*, 2012; 62(1):436-45.Sarantis K, **Antoniou K**, Matsokis N, Angelatou F. Exposure to novel environment is characterized by an interaction of D1/NMDA receptors underlined by phosphorylation of the NMDA and AMPA receptor subunits and activation of ERK1/2 signaling, leading to epigenetic changes and gene expression in rat hippocampus. *Neurochemistry International*, 2012; 60(1)55-67.Polissidis A, Galanopoulos A, Naxakis G, Papahatjis D, Papadopoulou-Daifoti Z, **Antoniou K**. The cannabinoid CB1 receptor biphasically modulates motor activity and regulates dopamine and glutamate release region dependently. *Int J Neuropsychopharmacol.* 2012;6:1-11.Rentesi G, **Antoniou K**, Marselos M, Syrrou M, Papadopoulou-Daifoti Z, Konstandi M. Earlymaternaldeprivation-inducedmodificationsintheneurobiological, neurochemical and behavioral profile of adult rats. *Behav Brain Res.* 2013; 1, 244:29-37.Sotiropoulou M, Mantas C, Bozidis P, Marselos M, Mavreas V, Hyphantis T, **Antoniou K**. BDNF serum concentrations in first psychotic episode drug-naïve schizophrenic patients: associations with personality and BDNF Val66Met polymorphism. *Life sciences* 2013; 92 (4):305-310.Bozidis P, Hyphantis T, Mantas C, Sotiropoulou M, Antypa N, Andreoulakis E, Serretti A, Mavreas V, **Antoniou**

- K.** HSP70 polymorphisms in first psychotic episode drug-naïve schizophrenic patients. *Life sciences* 2014; 100(2)133-137. Polissidis A, Chouliara O, Galanopoulos A, Naxakis G, Papahatjis D, Papadopoulou-Daifoti Z and **Antoniou K.** Cannabinoids negatively modulate striatal glutamate and dopamine release and behavioral output of acute D-amphetamine. *Behav Brain Res.* 2014; 270:261-9. Galanopoulos A, Polissidis A, Georgiadou G, Papadopoulou-Daifoti Z, Nomikos GG, Pitsikas N, **Antoniou K.** WIN55,212-2 impairs non-associative recognition and spatial memory in rats via CB1 receptor stimulation. *Pharmacol Biochem Behav.* 2014; 124:58-66. Kokras N, **Antoniou K,** Mikail HG, Kafetzopoulos V, Papadopoulou-Daifoti Z, Dalla C. Forced swim test: What about females? *Neuropharmacology.* 2015; 99:408-21. Kokras N, Polissidis A, **Antoniou K,** Dalla C. Head shaking in the forced swim test: A robust but unexplored sex difference. *PharmacolBiochemBehav.* 2016; pii:S0091-3057(16)30097-1. Gueye AB, Pryslawsky Y, Trigo JM, Poulia N, Delis F, **Antoniou K,** Loureiro M, Laviolette SR, Vemuri K, Makriyannis A, Le Foll B. The CB1 Neutral Antagonist AM4113 Retains the Therapeutic Efficacy of the Inverse Agonist Rimonabant for Nicotine Dependence and Weight Loss with Better Psychiatric Tolerability. *Int J Neuropsychopharmacol.* 2016; pii: pyw068. Delis F, Polissidis A, Poulia N, Justinova Z, Nomikos GG, Goldberg SR, **Antoniou K.** Attenuation of Cocaine-Induced Conditioned Place Preference and Motor Activity via Cannabinoid CB2 Receptor Agonism and CB1 Receptor Antagonism in Rats. *Int J Neuropsychopharmacol.* 2016; pii: pyw102. doi:10.1093/ijnp/pyw102. Delis F, Poulia N, Bozidis P, Sotiropoulou M, Paika V, Ntountoulaki E, Papaioannou D, Guthrie E, Carvalho A, **Antoniou K,** Hyphantis T. The impact of the burden of chronic illness upon depression is influenced by a polymorphism in the serotonin transporter gene. *Journal of Psychosomatic Research.* 2017; 97:144-145. **Antoniou K,** Polissidis A, Delis F, Poulia N. The impact of cannabinoids on motor activity and neurochemical correlates. *NeuroMethods,* 2017; 121:341-365. (Book chapter) Botsakis K, Mourtzi T, Panagiotakopoulou V, Vreka M, Stathopoulos GT, Pediaditakis I, Charalampopoulos I, Gravanis A, Delis F, **Antoniou K,** Zisimopoulos D, Georgiou CD, Panagopoulos NT, Matsokis N, Angelatou F. BNN-20, a synthetic microneurotrophin, strongly protects dopaminergic neurons in the "weaver" mouse, a genetic model of dopamine-denervation, acting through the TrkB neurotrophin receptor. *Neuropharmacology.* 2017 doi: 10.1016/j.neuropharm.2017.04.043. Kafetzopoulos V, Kokras N, Sotiropoulos I, Oliveira JF, Leite-Almeida H, Vasalou A, Sardinha VM, Papadopoulou-Daifoti Z, Almeida OF, **Antoniou K,** Sousa N, Dalla C. The nucleus reuniens: a key node in the neurocircuitry of stress and depression. *Mol Psychiatry.* 2018, doi: 10.1038/mp.2017.55.
- 30.** Pitsikas N, Georgiadou G, Delis F, **Antoniou K.** Effects of Anesthetic **Ketamine** on Anxiety-Like Behaviour in Rats. *Neurochem Res.* 2019 doi: 10.1007/s11064-018-02715-y
- 31.** Poulia N, Delis F, Brakatselos C, Lekkas P, Kokras N, Dalla C, **Antoniou K.** Escalating low-dose Δ^9 -tetrahydrocannabinol exposure during adolescence induces differential behavioral and neurochemical effects in male and female adult rats. *Eur J Neurosci.* 2019 doi: 10.1111/ejn.14598.

Total number of Publications: 78

Total number of Citations: 3250

Index h: 30

i 10 index: 55

(Source: Google Scholar)